Nick Simmonds is Professor of Practice (Respiratory Medicine) at the National Heart and Lung Institute (NHLI), Imperial College London and Associate Director of the Adult CF Centre at the Royal Brompton Hospital, London. His main research interests include difficult CF diagnosis and the investigation of novel CF therapies. He has been a Principal Investigator on numerous global multicentre trials and is on the Executive Committee of the European Cystic Fibrosis Society (ECFS) Clinical Trials Network. He has extensive experience of novel diagnostic techniques and is the Vice Coordinator of the ECFS Diagnostic Network. He is also on the Registry Research Committee of the UK CF Registry, a role which promotes the use of registries to better understand outcomes in CF.
et al., 2022, VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations., J Cyst Fibros
et al., 2022, Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme., J Cyst Fibros, Vol:21, Pages:434-441
et al., 2022, Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study., Journal of Cystic Fibrosis, Vol:21, ISSN:1569-1993, Pages:302-308
et al., 2021, Revisiting a diagnosis of cystic fibrosis - Uncertainties and considerations., Paediatr Respir Rev
et al., 2021, RESPIRATORY MICROBIOLOGY OUTCOMES FROM AN OBSERVATIONAL STUDY OF IVACAFTOR IN PEOPLE WITH CYSTIC FIBROSIS AND NON-G551D GATING MUTATIONS (VOCAL), BMJ PUBLISHING GROUP, Pages:A41-A41, ISSN:0040-6376